Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

To be able to join this study, people must have a confirmed diagnosis of Papillary Renal Cell Carcinoma (PRCC) that has spread or can't be removed by surgery. It's essential that their cancer has a specific genetic change called "MET-driven." Participants should not have had any previous drug treatments for their advanced cancer, nor have ever received savolitinib, durvalumab, or sunitinib in the past.

There are also some general health requirements, such as having good overall health, measuring at least 70 on a general health score (Karnofsky Score), and having healthy organ and bone marrow function. You'll also need to have at least one area of cancer that can be measured by doctors and be expected to live for at least 12 weeks.

Some conditions might prevent someone from joining, such as serious liver or heart problems, HIV or hepatitis infections, or certain autoimmune diseases. If you've had recent radiation to your spinal cord or brain tumours that are causing symptoms, or have had certain vaccinations recently, you might not be able to take part. The research team will carefully check all these details to make sure the study is right for you.

If you join this study, you'll be randomly assigned to one of three treatment groups. This means you have an equal chance of receiving one of the study treatments: savolitinib plus durvalumab, sunitinib, or durvalumab on its own. The treatments are given in different ways: savolitinib and sunitinib are taken as tablets by mouth once a day, while durvalumab is given as a drip into a vein every four weeks.

You will continue to receive the assigned treatment for as long as it is working for you, and you are not experiencing severe side effects. Doctors will regularly check your cancer using scans (like X-rays or CTs) to see how the treatment is working. They will also monitor your health closely through blood tests and other examinations to check for any side effects. If the cancer starts to grow, or if side effects become too severe, or if you decide you no longer wish to continue, the treatment will be stopped. Some patients in the durvalumab-only group might have the option to switch to the savolitinib and durvalumab combination if their cancer progresses.